# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Stifel analyst Stephen Willey maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $67 to $74.
Stifel analyst Stephen Willey maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $39 to $67.
TD Cowen analyst Ritu Baral maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $45 to $67.
UBS analyst Trung Huynh maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $46 to $58.
Goldman Sachs analyst Andrea Tan maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $49 to $74.
Wells Fargo analyst Tiago Fauth maintains Insmed (NASDAQ:INSM) with a Overweight and raises the price target from $55 to $77.
Truist Securities analyst Nicole Germino maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $48 to $68.